Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

medison pharma australia pty ltd - tebentafusp, quantity: 0.2 mg/ml - injection, concentrated - excipient ingredients: citric acid monohydrate; water for injections; mannitol; trehalose dihydrate; polysorbate 20; dibasic sodium phosphate - kimmtrak is indicated for the treatment of hla-a02 01-positive adult patients with unresectable or metastatic uveal melanoma.

India - inglise - Central Drugs Standard Control Organization

intra(invision) - permethrin - crm - 5%w/w - 30g

India - inglise - Central Drugs Standard Control Organization

intra(invision) - permethrin - lot - 5%w/v - 50ml

India - inglise - Central Drugs Standard Control Organization

intra(invision) - permethrin - soap - 1% - 75g

Iisrael - inglise - Ministry of Health

medison pharma ltd - efgartigimod alfa - concentrate for solution for infusion - efgartigimod alfa 20 mg/ml - efgartigimod - vyvgart is indicated for the treatment of generalized myasthenia gravis (gmg) in adult patients who are anti-acetylcholine receptor (achr) antibody positive.

Iisrael - inglise - Ministry of Health

medison pharma ltd - nusinersen - solution for injection - nusinersen 2.4 mg / 1 ml - spinraza is indicated for the treatment of 5q spinal muscular atrophy except type 0 and type iv.

Iisrael - inglise - Ministry of Health

medison pharma ltd - nusinersen - solution for injection - nusinersen 2.4 mg / 1 ml - spinraza is indicated for the treatment of 5q spinal muscular atrophy except type 0 and type iv.

Iisrael - inglise - Ministry of Health

medison pharma ltd - nusinersen - solution for injection - nusinersen 2.4 mg / 1 ml - spinraza is indicated for the treatment of 5q spinal muscular atrophy except type 0 and type iv.

Iisrael - inglise - Ministry of Health

medison pharma ltd - nusinersen - solution for injection - nusinersen 2.4 mg / 1 ml - spinraza is indicated for the treatment of 5q spinal muscular atrophy except type 0 and type iv.

Iisrael - inglise - Ministry of Health

medison pharma ltd - dinutuximab beta - concentrate for solution for infusion - dinutuximab beta 4.5 mg / 1 ml - dinutuximab - qarziba is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma, with or without residual disease. prior to the treatment of relapsed neuroblastoma, any actively progressing disease should be stabilised by other suitable measures.in patients with a history of relapsed/refractory disease and in patients who have not achieved a complete response after first line therapy, qarziba should be combined with interleukin-2 (il-2).